Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 13, Issue 8, 2007, Pages 975-980

  Cocco, E ^a   Marchi, P ^a   Sardu, C ^a   Russo, P ^b   Paolillo, A ^b,c   Mascia, M G ^a   Solla, M ^a   Frau, J ^a   Lorefice, L ^a   Massole, S ^a   Floris, G ^a   Marrosu, Maria G ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Brain MRI; Disability; Early stage; Mitoxantrone; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE; MITOXANTRONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISABILITY; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LEUKEMIA; MALE; MULTIPLE SCLEROSIS; RECURRENCE RISK; RELAPSE; UNSPECIFIED SIDE EFFECT; COHORT ANALYSIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE OF ONSET; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38449083112     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507077621     Document Type: Article

References (20)

1. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-71.
2. Lycklama à Nijeholt G, Barkhof F. Differences between subgroups of MS: MRI findings and correlation with histopathology. J Neurol Sci 2003; 206: 173-74.
3. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003; 61: 1332-38.
4. Rizvi SA, Zwibel H, Fox EJ. Mitoxantrone for multiple sclerosis in clinical practice. Neurology 2004; 63: S25-S27.
5. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
6. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-52.
7. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-93.
8. Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983; 10: 103-15.
9. Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998; 43: 499-506.
10. Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group.Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
11. Norman GR, Streiner DL. Biostatistica. Ambrosiana, 2000: 155-156.
12. Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006; 20: 2217-18.
13. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 2. Predicting value of early clinical course. Brain 1989; 112: 1419-28.
14. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-32.
15. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005; 23: 17-38.
16. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C et al. Therapeutic effect of mitox-antrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-18.
17. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-59.
18. Hartung HP, Gonsette R, Konig N, Kwiecinshi H, Guseo A, Morrissey SP et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
19. Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35-39.
20. Zingler VC, Nabauer M, Jahn K, Gross A, Hohlfeld R, Brandt T, Strupp M. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005; 54: 28-33.